AKATSUKI study: a prospective, multicentre, phase IV study evaluating the safety of emicizumab under and immediately after immune tolerance induction therapy in persons with congenital haemophilia A with factor VIII inhibitors

INTRODUCTION: For persons with haemophilia A with factor (F) VIII inhibitors (PwHAwI), immune tolerance induction (ITI) therapy is indicated for inhibitor eradication; however, since PwHAwI on ITI were excluded from the emicizumab clinical development programme, there are limited safety data for emi...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsushita, Tadashi, Suzuki, Nobuaki, Nagao, Azusa, Nagae, Chiai, Yamaguchi-Suita, Haruko, Kyogoku, Yui, Ioka, Akiko, Nogami, Keiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Haematology (Incl Blood Transfusion)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921931/
https://www.ncbi.nlm.nih.gov/pubmed/35288393
http://dx.doi.org/10.1136/bmjopen-2021-057018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921931/
https://www.ncbi.nlm.nih.gov/pubmed/35288393
http://dx.doi.org/10.1136/bmjopen-2021-057018

Ejemplares similares